Clincosm LogoSign in Get a demo

hnscc

Showing 1 - 25 of 49
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Breast Cancer, HNSCC Trial in Chang chun (YL202 should be intravenously infused)

Not yet recruiting
  • NSCLC
  • +3 more
  • YL202 should be intravenously infused
  • Chang chun, Jilin, China
    Jilin Provincial Cancer Hospital
Oct 25, 2023

Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

Withdrawn
  • Advanced Solid Tumor
  • +9 more
  • (no location specified)
Oct 16, 2023

HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)

Not yet recruiting
  • HPV-Related Squamous Cell Carcinoma
  • HNSCC
  • London, United Kingdom
    East and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023

HNSCC, Head Neck Cancer, Oropharynx Cancer Trial in Groningen (blood draws)

Recruiting
  • HNSCC
  • +4 more
  • blood draws
  • Groningen, Netherlands
    University Medical Center Groningen (UMCG)
Aug 23, 2023

HNSCC, Radiotherapy, PD-1 Trial in Guangzhou (PD-1inhibitor, concurrent chemoradiotherapy)

Recruiting
  • HNSCC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

HNSCC, Oral Cancer, PD-1 Trial in Guangzhou (Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses,

Recruiting
  • HNSCC
  • +2 more
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
  • Perbolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
  • Guangzhou, Guangdong, China
    Sun yat-sen memorial hospital
Aug 6, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

Recruiting
  • HNSCC
  • +5 more
  • DP CD8 TIL
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Jun 5, 2023

NSCLC, HNSCC, Melanoma Trial (CJRB-101, Pembrolizumab injection)

Not yet recruiting
  • NSCLC
  • +5 more
  • (no location specified)
Jun 1, 2023

Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma Trial in United States (MQ719,

Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • +18 more
  • Basking Ridge, New Jersey
  • +6 more
May 18, 2023

HNSCC Trial in Chengdu (Nituozumab)

Recruiting
  • HNSCC
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Apr 16, 2023

HNSCC Trial in Chengdu (Radiotherapy)

Recruiting
  • HNSCC
  • Radiotherapy
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Apr 16, 2023

HNSCC Trial (Danvatirsen, Pembrolizumab)

Not yet recruiting
  • HNSCC
  • (no location specified)
Apr 3, 2023

Breast Cancer, Gynecologic Cancer, HNSCC Trial in Boston (STX-478, Fulvestrant)

Recruiting
  • Breast Cancer
  • +3 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 13, 2023

Head Neck Cancer, Head Cancer, Head Cancer Neck Trial in United States (drug, procedure, radiation)

Recruiting
  • Head and Neck Cancer
  • +5 more
  • Basking Ridge, New Jersey
  • +5 more
Jan 19, 2023

Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC Trial in Australia, United States (RO7502175, Atezolizumab)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • +10 more
  • Aurora, Colorado
  • +6 more
Jan 4, 2023

HNSCC Trial in Worldwide (Eftilagimod alpha, Pembrolizumab)

Recruiting
  • HNSCC
  • Birmingham, Alabama
  • +28 more
Nov 29, 2022

Advanced Solid Tumor, Sarcoma, HNSCC Trial in China (T3011)

Recruiting
  • Advanced Solid Tumor
  • +6 more
  • T3011
  • Hefei, Anhui, China
  • +18 more
Oct 30, 2022

HNSCC Trial in Cincinnati, Cleveland, Philadelphia (Cesium-131, Pembrolizumab)

Recruiting
  • HNSCC
  • Cincinnati, Ohio
  • +2 more
Oct 4, 2022

Advanced Cancer, Ovarian Cancer, Lung Cancer Trial in United States (Dose escalation: COM902 monotherapy., Evaluation of

Recruiting
  • Advanced Cancer
  • +6 more
  • Dose escalation: COM902 monotherapy.
  • +3 more
  • Grand Rapids, Michigan
  • +5 more
Aug 8, 2022

Head and Neck Squamous Cell Carcinoma, HNSCC, Squamous Cell Carcinoma of the Larynx Trial (Cemiplimab-Rwlc)

Withdrawn
  • Head and Neck Squamous Cell Carcinoma
  • +4 more
  • (no location specified)
Aug 1, 2022

HNSCC Trial in United States (Tipifarnib, Alpelisib)

Recruiting
  • HNSCC
  • Duarte, California
  • +10 more
Jun 30, 2022

Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck Trial in Chicago (Carboplatin,

Recruiting
  • Human Papilloma Virus
  • +4 more
  • Chicago, Illinois
    University Of Chicago Medicine Comprehensive Cancer Center
Jun 3, 2022

Special Care Patterns for Elderly HNSCC Patients Undergoing

Recruiting
  • HNSCC
  • +4 more
    • New York, New York
    • +11 more
    Jun 2, 2022

    Circulating Tumor DNA Kinetics in Immuno-oncology

    Completed
    • Head and Neck Cancer
    • +4 more
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      May 16, 2022